Companies/Tilray Brands, Inc.

Company profile

Tilray Brands, Inc.

NASDAQ: TLRY · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Leamington, ONCIK 0001731348Reports USD

#172 of 1,394 Healthcare companies by revenue47th-percentile growth

EA Score

52D

FH 45DQ 62GM 46SS 69

v0.1 · 65/100 weight · provisional

↑ workforce scale, market scale · ↓ return on equity, return on assets

Methodology →

Revenue TTM

$1.2B

Rev growth YoY (TTM)

+3.1%

Net income (FY)

-$2.2B

Employees

2,650

Market cap

$554.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$821.3M$821.3M2025

Net income-$2.2B-$2.2B2025

Operating income-$2.3B-$2.3B2025

Total assets$2.1B$2.1B2025

Liabilities$584.8M$584.8M2025

Equity$1.5B$1.5B2025

Revenue trend

FY2020 – FY2025 · USD

$56.6M

FY20

$210.5M

FY20

$123.9M

FY21

$513.1M

FY21

$628.4M

FY22

$627.1M

FY23

$788.9M

FY24

$821.3M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Cannabis36%

Distribution Revenue30%

Beverage Alcohol Business28%

Wellness Business7%

By geography

EMEA39%

UNITED STATES33%

CANADA26%

Rest of World1%

The read

Tilray Brands, Inc. booked $821.3M in FY2025 revenue, growing 4.1% year over year — about the middle of the pack among Healthcare companies we track, at a -266.3% net margin.

Peers · Healthcare

Claritev Corporation61C Neurogene Inc.43D NeuroPace, Inc.54D Community Health Systems, Inc.74B

Key facts

CEOIrwin David Simon

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersLeamington, ON

ExchangeNASDAQ: TLRY

Employees2,650

IPO date2018-07-19

Latest filings

8-K2026-06-30 8-K2026-06-09 8-K2026-04-21 8-K2026-04-15 8-K2026-04-15 8-K2026-04-01 10-Q2026-04-01 8-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.